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ARTICLE
A systems-level framework for drug discovery
identiﬁes Csf1R as an anti-epileptic drug target
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Andree Delahaye-Duriez 1,4,5, Juliette Van Steenwinckel5, Pierre Gressens5,6, Benedicte Danis2,
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The identiﬁcation of drug targets is highly challenging, particularly for diseases of the brain.
To address this problem, we developed and experimentally validated a general computational
framework for drug target discovery that combines gene regulatory information with causal
reasoning (“Causal Reasoning Analytical Framework for Target discovery”—CRAFT). Using a
systems genetics approach and starting from gene expression data from the target tissue,
CRAFT provides a predictive framework for identifying cell membrane receptors with a
direction-speciﬁed inﬂuence over disease-related gene expression proﬁles. As proof of
concept, we applied CRAFT to epilepsy and predicted the tyrosine kinase receptor Csf1R as a
potential therapeutic target. The predicted effect of Csf1R blockade in attenuating epilepsy
seizures was validated in three pre-clinical models of epilepsy. These results highlight CRAFT
as a systems-level framework for target discovery and suggest Csf1R blockade as a novel
therapeutic strategy in epilepsy. CRAFT is applicable to disease settings other than epilepsy.
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Despite advances in our understanding of disease processesat the molecular and cellular levels, modern drug dis-covery has failed to deliver improved rates of approval for
mechanistically novel drugs1. One reason for the high rate of
attrition in drug development, particularly for diseases of the
central nervous system, is inadequate target validation in early-
stage drug discovery1,2. Optimism that advances in gene dis-
covery would facilitate the validation of mechanistically novel
drug targets has yet to materialize, and there is a requirement for
new approaches to target discovery and validation.
Network-based systems analyses provide powerful techniques
for elucidating molecular processes and pathways underlying
disease3–7. The power of the gene network approach comes from
the analysis of multiple genes in functionally enriched pathways,
as opposed to traditional single gene approaches that examine
only one component of a complex system at a time. Using
genome-wide transcriptional proﬁling in tissues relevant to the
disease under investigation, gene co-expression network analysis
can identify modules (i.e., sets of co-expressed genes) as candidate
regulators and drivers of disease states. Network-based drug
discovery aims to harness this knowledge to identify drugs cap-
able of restoring the expression of disease modules toward
health8,9. At this systems level, therapeutic compounds are judged
not by their binding afﬁnity to a particular protein, but by their
ability to induce a transcriptional response (i.e., a gene expression
proﬁle) that is anti-correlated to the coordinated transcriptional
program underpinning the disease state. This systems approach
to disease modiﬁcation is loosely termed the “signature reversion
paradigm” and is orthogonal to traditional concepts of drug
discovery.
Currently, drugs capable of reversing disease-related tran-
scriptional signatures are identiﬁed using two main strategies.
One approach uses public databases of transcriptomic proﬁles of
cell lines treated with chemical compounds and seeks a chance
anti-correlated overlap between a drug’s gene expression proﬁle
and a disease’s gene expression signature10. Whilst successful
examples for the use of such “perturbation databases” have
emerged11,12, new targets are not identiﬁed by this route and the
method’s reliance on chance overlap in expression proﬁles means
a very large number of drugs may need to be proﬁled to ﬁnd one
with a suitable proﬁle13. A second approach has therefore
emerged that aims to map the underlying drivers and regulators
of disease-related gene expression signatures as candidate drug
targets7. Successful examples include mapping the upstream
regulators of disease modules using expression quantitative trait
loci mapping14,15, and approaches that make use of regulatory
interactions between genes (“regulomes”)16. As currently for-
mulated, however, these approaches also have limitations. For
example, expression quantitative trait loci mapping of networks
may identify only large genomic regions in which several candi-
date genes could be equally implicated whilst regulome approa-
ches are not currently formulated to speciﬁcally identify
regulators that have tractability as drug targets.
Given these constraints we aimed to develop a new framework
for drug target discovery based on identifying the regulators of
disease-associated gene co-expression modules. Our method,
“Causal Reasoning Analytical Framework for Target discovery”
or CRAFT, combines gene regulatory information with a causal
reasoning framework to computationally predict cell surface
receptors with a direction-speciﬁed inﬂuence over module
activity. We speciﬁcally chose to develop a method connecting
module expression to membrane receptors because more than
half of all approved drugs target receptors17, thus maximizing the
opportunity for drug repositioning and rapid experimental
medicine proofs of principle. Although in this study we applied
CRAFT to epilepsy, CRAFT is equally applicable to any disease
for which an underlying disease expression signature can be
identiﬁed.
We chose to study epilepsy using CRAFT for two main rea-
sons. Firstly, epilepsy is a highly debilitating disease of the brain
for which there is a global unmet need—approximately one in
three epilepsy patients are resistant to all currently available
antiepileptic drugs (AEDs) and none of the current drugs are
disease modifying or curative18. Secondly, epilepsy is a disease
beneﬁting from well-characterized pre-clinical models with pro-
ven relevance to the human disease, and indeed, pre-clinical
testing in rodent models of epilepsy remains the mainstay for
determining efﬁcacy of candidate antiepilepsy drugs19. This
attribute allowed the development and validation of CRAFT in a
controlled experimental framework.
Epilepsy itself is a disease characterized by recurrent unpro-
voked epileptic seizures, but is also associated with additional
features including cognitive and behavioral impairments and a
heightened risk of death20. The causes of epilepsy can be broadly
divided into cases that arise through no cause other than a genetic
predisposition (“genetic epilepsy”), and epilepsy which develops
secondary to an acquired brain injury such as following status
epilepticus (SE) or head injury (“acquired epilepsy”)21. Here,
focusing on acquired epilepsy, we set ourselves the challenge of
developing, implementing, and validating a computational
method for inferring drug targets for epilepsy from disease-
related gene expression data.
Results
Identiﬁcation of candidate gene networks for epilepsy. A
summary and description of the study workﬂow is shown in Fig.
1. As a ﬁrst step, we aimed to identify gene co-expression net-
works (i.e., modules) associated with epilepsy. To this end, we
used an established post SE mouse model of acquired temporal
lobe epilepsy (TLE)22. In this model of epilepsy the mice develop
spontaneous recurrent seizures approximately 4 weeks after
pilocarpine-induced SE. As well as manifesting spontaneous
epileptic seizures, these mice also reﬂect several of the behavioral
and cognitive disturbances associated with TLE in humans, and
their response to AED therapy has been shown to be predictive of
drug efﬁcacy in human epilepsy23.
High-throughput sequencing of mRNA (RNA-sequencing
(RNA-seq)) was performed on whole hippocampus samples from
100 outbred epileptic mice and 100 control (i.e., pilocarpine-
naïve) littermate mice (see Methods). In total, 14,188 genes were
expressed (Log2 FPKM >0) in at least 5% of samples, and of these,
9013 genes showed signiﬁcant (false discovery rate (FDR) <0.05)
differential expression (DE) between epileptic and healthy control
mice (Supplementary Data 1).
To identify gene co-expression modules related to epilepsy, the
set of genes expressed in the mouse epileptic hippocampus
samples were ﬁrst clustered according to their co-expression
relationships. Brieﬂy, Spearman’s rank correlation coefﬁcients of
expression were computed for all gene pairs and the pairwise
correlation coefﬁcients were used to perform hierarchical
clustering based on Ward’s method24. The optimal number of
co-expression modules was calculated using Elbow’s and pseudo
F-index method25 (Supplementary Figure 1). This led to the
identiﬁcation of 28 co-expression modules and an additional gene
set (termed “module” 3) consisting of un-clustered genes (see
Supplementary Data 2 for the full list of modules and their
constituent genes). The 28 co-expression modules varied in size
between 78 and 1036 genes (mean and median module size was
255 and 188 genes, respectively).
Analysis of the biological terms and canonical pathways
enriched among the 28 co-expression modules in the mouse
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epileptic hippocampus revealed that the modules were generally
enriched for speciﬁc functions—the top Gene Ontology (GO)
biological processes enriched in each module are shown in
Supplementary Figure 2a. The results of the functional enrich-
ment analysis for each module are reported in full in
Supplementary Data 3. Among the modules with overlapping
functions, modules 5, 16, and 18 were enriched for “immune
response” processes (Benjamini–Hochberg (BH)-corrected P=
2.1 × 10−11, P= 1.4 × 10−6, and P= 1.3 × 10−33, respectively),
and modules 10, 14, 26, and 29 were enriched for neuronal
functions including “synaptic transmission” (BH P= 4.4 × 10−11,
P= 0.02, P= 4.0 × 10−3, and P= 4.0 × 10−4, respectively).
To provide insights into the cell-type expression of the
modules, we used cell-type marker genes derived from single-
cell RNA-seq analysis of the mouse hippocampus (see Methods)
26. The individual modules demonstrated notable cell-type
speciﬁcity (Supplementary Figure 2b and Supplementary Data 4).
The cell-type speciﬁcity of a module broadly corresponded to its
functional enrichment. For example, “immune response” mod-
ules 16 and 18 were enriched for microglia marker genes, whilst
“synaptic transmission” modules 10, 14, 26, and 29 were speciﬁc
for neuronal cell types.
To prioritize modules with a potential relationship to epilepsy,
we undertook a staged set of analyses summarized in Supple-
mentary Figure 3. First, we tested if any of the modules were
speciﬁc to the epileptic hippocampus using differential co-
expression analysis. The differential co-expression paradigm
postulates that a disease is linked to co-expression patterns that
are different in disease compared to healthy states, reﬂecting
perturbed functional processes. Using methodology formulated
by Choi and Kendziorski27 (see Methods), 12 modules were
found to be signiﬁcantly (FDR <0.05) differentially co-expressed
between the epileptic and control hippocampus, whilst 16
modules displayed conservation of co-expression (Supplementary
Figure 4 and Supplementary Data 5). Of the 12 differentially co-
expressed modules, modules 5, 16, and 18 were enriched for
functional terms related to immune response processes, whilst
modules 8, 10, and 21 were enriched for synaptic transmission
and/or neuronal plasticity. As expected, the 16 modules with
similar co-expression patterns in epileptic cases and controls were
generally enriched for “housekeeping” functional terms unrelated
to epilepsy, such as cell morphogenesis and protein transport.
To further prioritize the modules in terms of their relationship
to epilepsy, we explored the correlation between each module’s
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Fig. 1 Experimental plan and study overview. We studied 100 mice with epilepsy (pilocarpine post status epilepticus model of temporal lobe epilepsy) and
100 control (pilocarpine-naïve) matched littermate mice. At 4 weeks post status epilepticus, each mouse was continuously monitored using 3D
accelerometry and video monitoring for 14 days to record seizure frequency and severity. High-throughput mRNA sequencing (RNA-seq) was generated
using RNA from snap-frozen whole hippocampus samples from the mice and gene expression proﬁles were used to generate co-expression modules. Co-
expression modules with a potential relationship to epilepsy were prioritized using the following criteria: (i) differential co-expression between epileptic and
healthy hippocampus (mouse and human TLE), (ii) correlation of module expression with seizure frequency (mouse), and (iii) conservation in the human
epileptic hippocampus. Modules meeting these criteria were considered candidate modules for epilepsy, and subjected to CRAFT analysis to identify
membrane receptors predicted to restore disease module expression toward health
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expression and seizure frequency. To this end, we ﬁrst quantiﬁed
the frequency of behavioral seizures in each epileptic mouse by
14 days of continuous motion sensing 3D accelerometry
synchronized with continuous video monitoring (see Methods).
This revealed a diurnal variation of seizure occurrence in mice as
well as clustering of seizures reﬂective of the classical patterns of
human TLE (Supplementary Figure 5)28. Next, we summarized
each module’s expression by its eigengene (i.e., its ﬁrst principal
component, PC1) and calculated the correlation between each
module’s eigengene and seizure frequency. Of the 12 differentially
co-expressed modules, nine (modules 2, 5, 8, 10, 16, 18, 21, 22,
and 24) had an eigengene that signiﬁcantly (FDR <0.05)
correlated with seizure frequency (Fig. 2a).
To explore the relationship between a module and epilepsy in
more detail, we correlated the expression of each individual gene
in a module with seizure frequency using quantitative traits
transcript (QTT) analysis29. Across all modules, 833 genes had
expression levels that signiﬁcantly (FDR <0.05) correlated with
seizure frequency (hereon termed “QTT genes”) (Supplementary
Data 7). To assess the overall direction of correlation between a
module and epileptic seizures, we plotted the average correlation
of expression of genes in a module with seizure frequency against
the module’s enrichment for QTT genes (Fig. 2b). Considering
the nine modules differentially co-expressed in epilepsy and
correlated with seizures by module eigengene (i.e., modules 2, 5,
8, 10, 16, 18, 21, 22, and 24), module 18 (enriched for
inﬂammatory processes and expressed in microglia) was the
module most signiﬁcantly positively correlated with seizures,
whilst module 10 (synaptic transmission) was the module most
signiﬁcantly negatively correlated with seizures. This anti-
correlation between down-regulated modules enriched in synap-
tic functions and up-regulated modules enriched in inﬂammatory
microglial pathways has also been described in autism spectrum
disorder30.
For the nine modules differentially co-expressed in epilepsy
and correlated with seizures (i.e., modules 2, 5, 8, 10, 16, 18, 21,
22, and 24), we then assessed whether the module was conserved
in the human epileptic hippocampus. Using human orthologs of
mouse module genes and genome-wide gene expression data
from 122 human epileptic hippocampus samples surgically
ascertained from TLE patients14, we found that all nine modules
were conserved in the human epileptic hippocampus (FDR <0.05)
(Supplementary Data 6). The conservation of these nine modules
across human and mouse TLE provides an independent line of
evidence for the validity of these modules, and further supports
the relevance of the pilocarpine post SE mouse model of TLE to
human TLE14.
As a ﬁnal assessment of the relationship of these nine mouse
TLE modules to human epilepsy, we tested whether each module
was also differentially co-expressed in human TLE. In this
analysis, for each module, we compared intra-module correla-
tions in the human epileptic hippocampus with that in the non-
diseased human hippocampus using post-mortem hippocampal
samples ascertained from people with no history of psychiatric or
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Fig. 2 Correlation of module expression with seizures. a For each co-expression module from the epileptic mouse hippocampus, we plotted the signiﬁcance
(−Log10 FDR) of the Spearman’s correlation between the module’s eigengene and seizure frequency (bar plot), and the percentage of variance in seizure
frequency explained by the module’s eigengene (R2, dotted line). Modules marked with a blue arrow are the modules differentially co-expressed between
the epileptic mouse hippocampus and the control mouse hippocampus. Modules highlighted in gray (bar plot) are signiﬁcantly (FDR <0.05) correlated with
seizure frequency. b Volcano plot of average (Spearman’s) correlation of a module’s genes with seizure frequency (X-axis) versus the signiﬁcance of the
module’s enrichment for genes individually correlated with seizure frequency (QTT genes) (Y-axis) for the nine modules differentially co-expressed in
epilepsy and correlated with seizures by module eigenegene
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neurological disease (see Methods)31. Among the nine mouse
modules differentially co-expressed in epilepsy and correlated
with seizures, seven (5, 10, 16, 18, 21, 22, and 24) were also
differentially co-expressed in human TLE (Supplementary
Data 6). These seven modules were selected for further analysis.
Speciﬁcally, we hypothesized that focusing on these seven
modules (and by extension their enriched functional pathways)
would provide a starting point for the development of new
therapies for epilepsy.
Before proceeding to mapping the upstream regulators of these
modules as candidate drug targets for epilepsy, since an
important goal of our study was to identify mechanistically new
drugs for epilepsy, we asked whether any of the seven modules
could be considered to have a “known” relationship to epilepsy
based on the published biomedical literature (see Methods).
Brieﬂy, we ﬁrst extracted published Abstracts for every gene in
the genome using SCAIview webserver (www.scaiview.com)
(3,811,179 abstracts with at least one gene–Abstract pair). The
weight of evidence relating a particular gene to epilepsy was then
quantiﬁed by determining if that gene’s co-citation with epilepsy
(23,092 Abstracts with at least one gene–epilepsy co-citation) was
more frequent than expected by chance (hypergeometric test,
Supplementary Data 8). Then, by considering gene–epilepsy pairs
signiﬁcant at FDR <0.05, the modules were ranked according to
their enrichment of gene–epilepsy pairs (hypergeometric test,
Supplementary Data 9). Of the seven candidate epilepsy modules
prioritized above, only module 10 (enriched for neuronal
processes) was signiﬁcantly (FDR <0.05) enriched for genes with
a “known” relationship to epilepsy, suggesting the remain-
ing modules may be capturing novel functional relationships
with epilepsy.
Drug target prioritization through causal reasoning (CRAFT).
The above analyses prioritized seven modules (5, 10, 16, 18, 21,
22, and 24) as candidate modules for epilepsy by virtue of being
(a) differentially co-expressed in mouse and human TLE, (b)
conserved across mouse and human TLE, and (c) correlated with
seizure frequency. From the pragmatic perspective of drug dis-
covery, we set out to identify regulators of each of these modules
as potential antiepilepsy drug targets.
According to the signature reversion paradigm, if a module’s
expression is causally related to the disease, then restoration of
the disease module’s expression toward the healthy state should
be predictive of therapeutic beneﬁt. We therefore set out to
identify a drug-able target capable of restoring the activity of one
or more candidate epilepsy module toward health. Since
approximately 60% of existing drugs in clinical use target
membrane receptors17, we decided to focus our search on ﬁnding
membrane receptors exerting a regulatory inﬂuence over module
activity. To this aim, we developed and implemented a
computational approach that combines “causal reasoning” with
gene regulatory information to rank receptors based on the
strength of their predicted effect on module expression (see
Methods). Brieﬂy, using Clarivate Analytics MetaBase® (version
6.15.62452), we ﬁrst extracted information relating to known
interactions between membrane receptors and transcription
factors (TFs) via linear canonical pathways and then between
TFs and their target genes. To provide context to this
“interactome,” only membrane receptors, TFs, and target genes
expressed in the mouse hippocampus were considered (resulting
in a list of 1624 expressed TFs and 307 expressed receptors). In a
causal reasoning framework (logic summarized in Fig. 3), there
are multiple scenarios by which a membrane receptor can act via
TFs on the set of genes in a module that are dysregulated in
disease. For each of these scenarios, the direction of effect of a
membrane receptor on TFs and of the TFs on target genes is
deﬁned by a causal reasoning argument, which takes into account
the directionality of the receptor > TF > target gene interactions
and whether the network genes are over-expressed or under-
expressed in the disease state. For each scenario (Fig. 3), the
signiﬁcance of the inﬂuence of a membrane receptor on a
module’s gene expression can be quantiﬁed by considering the
overlap between the direction-speciﬁed receptor effects on gene
expression with the genes in a module that are over-expressed or
under-expressed in epilepsy (hypergeometric test; see Methods
and Supplementary Figure 6). This process allows membrane
receptors to be ranked in terms of their predicted effect on
module expression and the direction of that effect in terms of
either activating or repressing the disease state, allowing the
therapeutic directionality of receptor blockade or activation to be
inferred.
Of the seven candidate epilepsy modules, four (5, 16, 18, and
22) were signiﬁcantly (FDR <0.05) enriched for one or more
direction-speciﬁed receptor effect on module expression (Supple-
mentary Data 10) (for intermediate TF effects on module
expression, see Supplementary Data 11). For each of these
receptors, we plotted the proportion of genes in a module targeted
by the receptor against the module’s –Log10 FDR enrichment for
receptor (direction-speciﬁed) target genes, allowing membrane
receptors to be visualized in terms of their predicted directionality
on the genes in a module which are over-expressed or under-
expressed in disease, as well as the speciﬁcity and magnitude of
the predicted effect (Supplementary Figures 7a–d). In support of
the validity of our causal reasoning results, we found that
membrane receptors related to interleukin-1 type 1 receptor and
Toll-like receptor 4 had a predicted direction of effect on epilepsy
via a module enriched for relevant functional processes that was
in agreement with the previously reported experimental evidence
for that receptor32.
Of the many membrane receptors predicted to signiﬁcantly
inﬂuence the expression of module genes in a direction-speciﬁed
manner, macrophage colony-stimulating factor (M-CSF) receptor
(also known as colony-stimulating factor 1 receptor encoded by
the Csf1R gene in the mouse) was predicted to be a regulator of
two of the seven prioritized candidate epilepsy modules (modules
18 and 22, P= 0.017 and P= 0.031, respectively). For both these
modules, Csf1R was predicted by CRAFT to “activate” the subset
of genes in the module that are over-expressed in epilepsy.
According to the CRAFT causal reasoning framework (Fig. 3),
small molecule blockade of Csf1R should therefore be therapeutic
in epilepsy (i.e., reduce seizures) and restoration of module
expression toward health by Csf1R inhibition should be predictive
of therapeutic beneﬁt. The availability of the known Csf1R
inhibitor PLX339733 provided us with a tool compound by which
to experimentally test this hypothesis. Moreover, Csf1R has not
previously been linked to epilepsy, allowing the opportunity for
novel target discovery. We therefore chose to prioritize Csf1R for
further analysis.
Csf1R regulates module 18 genes. To test the predicted reg-
ulatory inﬂuence of Csf1R on modules 18 and 22, we ﬁrst
selected three genes in each module as markers of module
expression (Emr1, Aif1, Irf8, Gfap, ItgA5, and Serpine1) on the
basis that these genes (a) belonged to either module 18 or 22
and were among the set of genes predicted by CRAFT to be
positively regulated by Csf1R, (b) are over-expressed in epi-
leptic cases compared to controls, and (c) are not predicted to
be regulated by c-Kit (a kinase also inhibited by PLX3397)34.
Epileptic mice were treated with PLX3397 at 3 or 30 mg/kg
per day or vehicle for 7 days (see Methods). Hippocampus RNA
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was extracted on day 7 and gene expression was measured by
reverse transcriptase quantitative PCR (qPCR). Csf1R blockade
with PLX3397 at 30 mg/kg per day was associated with a sig-
niﬁcant decrease in the marker genes of module 18 but not
module 22 (Fig. 4a).
To conﬁrm the regulatory inﬂuence of Csf1R on module 18,
and to investigate the transcriptional response of module 18 to
Csf1R blockade in more detail, we assayed the expression of all
171 genes in module 18 in response to PLX3397 treatment. Here,
mice with epilepsy were treated with PLX3397 at 3 or 30 mg/kg
per day or vehicle alone. Hippocampal mRNA was extracted on
day 14 of treatment and module 18 expression was assayed by
microarray (see Methods). In keeping with CRAFT prediction, we
observed a signiﬁcant (P < 2.2x10−16) and dose-dependent (P=
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Fig. 3 Causal reasoning framework. A knowledge-based “interactome” (or "regulome") connecting membrane receptors to module gene expression was
constructed based on experimentally validated connections between membrane receptors and transcription factors (TFs) in linear pathways, and between
TFs and their target genes (genome-wide). This “regulome” is then integrated with information about whether the genes in a candidate module are over-
expressed (“O”) or under-expressed (“U”) in the disease state, allowing receptors to be classiﬁed as either disease “Activators” or “Repressors,” which in
turn permits the therapeutic directionality of receptor blockade or activation to be inferred. In the upper part of the ﬁgure, we show the positive activation
of the TFs by the receptor “Receptor A,” whereas in the lower part of the ﬁgure we show the opposite scenario of inactivation of the TFs by Receptor A. An
illustrative example of the framework is shown in Supplementary Figure 6
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3.6x10−14) restoration of module 18 expression toward health
following treatment with PLX3397 (Fig. 4b).
These results are consistent with a shift in the expression of
module 18 in epilepsy toward the healthy state following
PLX3397 exposure. However, module 18 is predicted to be highly
expressed in microglia (Supplementary Figure 2b), and it has
been suggested that PLX3397 may deplete the brain microglial
cell population as judged by Iba1 immunolabeling33. Using
epileptic mouse cortex and hippocampus samples following
treatment with PLX3397, we observed a similar decrease in Iba1
immunolabeling (Supplementary Figure 8). However, Iba1
(encoded by Aif1) is both a component of module 18 and a
predicted regulatory target of Csf1R and therefore Iba1 staining
alone cannot distinguish between depletion of microglia cells by
PLX3397 or a more focused down-regulation in Aif1 gene
expression. To distinguish between these two possibilities we
undertook a series of further analyses.
First, since module 18 is only one of three microglial modules
(the others being modules 16 and 24), if the measured change in
expression of module 18 following PLX3397 treatment is a
consequence of microglia cell loss rather than a focused
transcriptional change, then all three modules should be enriched
for genes down-regulated by PLX3397. Of these three modules,
however, only module 18 was enriched (FDR <0.01) for genes
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vehicle or PLX3397 at 3 or 30mg/kg per day (n= 8 mice in each group). At the end of the treatment, hippocampal RNA was extracted and the expression
of marker genes in modules 18 and 22 was assayed by rt-qPCR. Module 18 marker genes were signiﬁcantly down-regulated by PLX3397 at 30mg/kg
per day (*P < 0.05, **P < 0.01—one-tailed Welch’s t test). b Restoration of module 18 expression in epilepsy toward health by PLX3397. Epileptic mice were
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for 2 h to assess drug efﬁcacy. Treatment with PLX3397 led to a signiﬁcant (*P < 0.05) reduction in the duration of HPDs. e Efﬁcacy of PLX3397 in
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In total, 60 hippocampal slices from six rats were analyzed consisting of 36 slices for control and 24 for PLX3397 treatment groups, respectively. *P < 0.05
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down-regulated by PLX3397 (Supplementary Figure 9), suggest-
ing a selective effect on module 18 expression by PLX3397 as
opposed to a global down-regulation of microglial modules due to
gross microglial depletion. Consistent with this interpretation, we
observed that the expression of the microglia-speciﬁc gene Sall135
was up-regulated by PLX3397 (Log2 fold change= 0.17, FDR=
2.16x10−6).
We then investigated the effect of PLX3397 on mouse primary
microglia cells in vitro (see Methods). Supplementary Figure 10
shows that treatment of both activated and basal microglia with 1
µM PLX3397 is not associated with detectable microglial cell
death as assayed by immunocytoﬂuorescence.
We then assessed the effect of PLX3397 on the microglial
transcriptome in primary microglia cells, again assessing the
effect of PLX3397 in basal and activated states. For these
experiments, we generated genome-wide RNA-seq proﬁles for
each of the following four conditions (1) basal microglia,
untreated, (2) basal microglia, PLX3397 treated, (3) activated
microglia, untreated, and (4) activated microglia, PLX3397
treated. The full list of microglia genes differentially expressed
following treatment with PLX3397 in basal and activated
microglia are reported in Supplementary Data 12 and 13,
respectively. Using the list of genes differentially expressed in
microglia by PLX3397, we investigated whether PLX3397 could
induce pathways for programmed cell death. We curated gene
lists for all known pathways related to apoptosis from GO,
KEGG, Panther, Reactome, and Wiki pathways (total number of
apoptosis gene sets= 81), and tested whether any of these
pathways were induced by PLX3397 using gene set enrichment
analysis. Of the 81 pathways, none were signiﬁcantly (FDR <0.05)
induced by PLX3397 in microglia in either basal (Supplementary
Data 14) or activated (Supplementary Data 15) states. In contrast,
we observed that module 18 is highly signiﬁcantly down-
regulated by PLX3397 in primary microglia in both basal (P=
< 1.0 × 10−5) and activated (P < 1.0 × 10−5) states (Supplemen-
tary Data 16).
Taken together, these analyses point to a PLX3397-dependent
reversion of module 18 expression in epilepsy toward health via
Csf1R inhibition. Under the signature reversion paradigm, if
module 18 has been correctly assigned as a driver of epileptic
seizures then PLX3397 treatment should exert a therapeutic effect
in epilepsy. We decided to test this prediction by investigating the
therapeutic effect of PLX3397 in pre-clinical models of epilepsy.
Pre-clinical assessment of Csf1R inhibition. We ﬁrst assessed
PLX3397 efﬁcacy in epilepsy using the same pilocarpine model of
TLE used to generate the gene expression data for our co-
expression analyses (above). Epileptic mice underwent 14 days of
continuous motion sensing 3D accelerometry synchronized with
continuous video monitoring to determine their baseline seizure
frequency. This was followed by daily treatment with PLX3397 (3
or 30 mg/kg per day) or vehicle alone (20 mice in each group) for
14 days with continuous monitoring of seizures during the
treatment phase. Treatment of epileptic mice with PLX3397 30
mg/kg per day resulted in a signiﬁcant (P < 0.01) decrease seizure
frequency (Fig. 4c). Mortality was recorded to ensure no differ-
ences in the severity of SE between the groups or treatment effects
on survival: one mouse died in the 3 mg/kg per day arm, one
mouse died in the 30 mg/kg per day arm, and no lethality was
recorded in the pilocarpine/vehicle arm.
Next, to conﬁrm the therapeutic effect of PLX3397 on
epileptic seizures, we repeated the efﬁcacy analysis using the
mouse intrahippocampal kainate model of TLE (see Methods)
36. Here, seizure activity was assessed using electroencephalo-
graphic (EEG) recordings23. The primary clinical outcome was
reduction in the duration of hippocampal paroxysmal dis-
charges (HPDs) in response to PLX3397 treatment, which is a
standard efﬁcacy outcome measure in this epilepsy model. In
the kainate model, treatment with standard AEDs usually only
achieves a reduction in HPD duration at supra-therapeutic
doses, suggesting the kainate model is a model of drug-resistant
epilepsy37. Epileptic mice were EEG monitored at baseline (day
0) for 2 h prior to daily administration of PLX3397 at 30 mg/kg
per day for 4 days and then EEG monitored again on day 5 for
2 h to assess drug efﬁcacy. Treatment with PLX3397 was
associated with a signiﬁcant (P < 0.05) reduction in the duration
of HPDs (Fig. 4d).
Finally, to provide further evidence for the anti-seizure effect of
PLX3397, we then assessed PLX3397 efﬁcacy using the ex vivo
organotypic hippocampal slice culture (OHSC) model of
epilepsy38. Whilst pre-clinical testing in animal models remains
the mainstay for determining efﬁcacy of candidate antiepilepsy
drugs19, ex vivo OHSCs retain many of the key phenotypic
features of acquired epilepsy including a latent period prior to the
occurrence of spontaneous ictal events39, and the developmental
sequence of interictal spikes to spontaneous ictal events in
OHSCs closely mimics the temporal progression observed in the
kainate model of epilepsy40. The ex vivo OHSC model of epilepsy
therefore allows a multidimensional assessment of PLX3397
efﬁcacy and mechanism beyond the in vivo models considered
above. For example, because OHSCs represent tissue isolated
from the systemic blood supply or wider brain, the development
of epilepsy in OHSC’s reﬂects the intrinsic properties of the
hippocampal slice isolated from potential inﬁltration of exogen-
ous inﬂammatory (or other) cell types. In Fig. 4e we report the
assessment of PLX3397 on epileptiform activity in OHSCs using
multi-electrode arrays (MEAs) (see Methods for experimental
details). As with the kainate mouse model of epilepsy, treatment
with PLX3397 led to a signiﬁcant (P < 0.05) reduction in the
duration of ictal events. Concurrent assessment of lactate
dehydrogenase (LDH) in the OHSC culture supernatants at
baseline before PLX3397 exposure and after the ﬁrst and second
week of PLX3397 treatment revealed no evidence that the anti-
seizure effect of PLX3397 was dependent on microglial (or other)
cell death (Fig. 4e).
To assess the speciﬁcity of Csf1R blockade by PLX3397, we
investigated the pharmacokinetics (PKs) of PLX3397 in mice (see
Methods). First, we wanted to conﬁrm sufﬁcient duration of
exposure of PLX3397 following oral gavage. Following treatment
of epileptic mice (pilocarpine model) at 3 and 30 mg/kg per day
(per os (p.o.)) for 1 week (8 mice in each group), we analyzed
PLX3397 levels in the plasma and brain (the latter 24 h after the
last oral administration). Supplementary Figure 11A shows that
PLX3397 concentrations were stable for the 24 h period following
last oral administration of a 30 mg/kg dose (the therapeutic dose
in this animal model of epilepsy) with a free (i.e., protein
unbound active) concentration in the mouse brain of approxi-
mately 1 nM. Mean free plasma concentrations measured 24 h
after the last administration were 0.6 ± 0.2 and 13 ± 2 nM for 3
and 30 mg/kg doses, respectively, and mean free brain concen-
trations were 0.06 ± 0.02 and 1.0 ± 0.13 nM, respectively (Supple-
mentary Figure 11B). Our results conﬁrm that approximately 5%
of PLX3397 enters the brain after oral administration as
previously reported33. In cellular assays of
PLX3397 selectivity41, the half maximal inhibitory concentration
(IC50) of PLX3397 for inhibiting Csf1R is 20 nM, compared to
IC50s for c-Kit and Flt3 of 120 nM and 1.7 μM, respectively
(Supplementary Figure 11B) indicating that free brain concentra-
tions of PLX3397 attained after 30 mg/kg per day oral gavage are
within a range for Csf1R kinase activity, but substantially below
that of either c-Kit or Flt3.
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Taken together, these drug efﬁcacy, cell viability, and gene
expression analyses are consistent with microglial Csf1R inhibi-
tion exerting a therapeutic effect in acquired epilepsy in the
absence of microglial depletion. We therefore evaluated whether
PLX3397 has a detectable effect on the microglial phenotype (see
Methods).
We ﬁrst assessed the microglia phenotype using ex vivo brain
slices from epileptic mice (pilocarpine model) treated with vehicle
or PLX3397 at 30 mg/kg (the therapeutic dosage in epileptic
mice). Analysis of phagocytic function assessed by pH-sensitive
rhodamine-labeled zymosan particle uptake revealed no signiﬁ-
cant differences in the number of particles taken up by microglia
in the brain slices of vehicle or PLX3397-treated mice
(Supplementary Figure 12A). In keeping with the evidence from
ex vivo hippocampal slices and in vitro primary microglia cell
viability assays (above), we found no evidence that PLX3397
impacts microglia cell viability as measured by LDH activity in
the brain slice supernatant (Supplementary Figure 12A). We then
assessed microglia morphology in brain slices from vehicle and
PLX3397-treated epileptic mice and identiﬁed that microglia in
epileptic mice brains exposed to PLX3397 have thicker healthier
processes compared to the highly ﬁlamentous discontinued
ﬁlopodia in epileptic mice treated with vehicle alone (Supple-
mentary Figure 12B). Finally, using mouse primary microglia, we
assessed the effect of PLX3397 on microglial cell migration using
the in vitro scratch assay. At 24 h we observed a signiﬁcant
decrease in the motility of microglia exposed to 1 µM PLX3397
(Supplementary Figure 12C) and again conﬁrmed the viability of
microglia cells at 1 µM PLX3397 concentration (Supplementary
Figure 12D).
Overall, these data point to PLX3397 having a disease context-
speciﬁc effect on epilepsy via module 18 as predicted by CRAFT.
Therefore, to provide further evidence for PLX3397’s context-
speciﬁc effect on epilepsy (i.e., consistent with its measured effect
on module 18 gene expression and the microglial phenotype), we
investigated whether PLX3397 has anti-seizure effects in normal
(non-epileptic) mice induced to have seizures (see Methods). For
these studies, we used three different acute seizure models, the
maximal electroshock seizure (MES) model, the electrical 6 Hz
psychomotor model and the chemical pentylenetetrazol (PTZ)
model. In Supplementary Figure 13, we show that neither single
dose PLX3397 nor chronic pre-treatment with PLX3397 has any
anti-seizure effects in any of the acute seizure models across a
broad range of outcome measures. These data clearly distinguish
PLX3397 from all standard AEDs, which are effective in at least
one of these acute seizure models, and indeed, the MES, 6 Hz, and
PTZ acute seizure models have been the traditional gatekeepers
for new AED discovery for over half a century42.
Discussion
In this study, we used a gene network perspective of disease as a
landscape for drug discovery. Under this framework, restoration
of disease-related module expression toward health is considered
to be predictive of therapeutic beneﬁt, allowing “target” validation
at the earliest stage of the drug discovery process. Based on this
premise, we set out to develop and validate a predictive gene
regulatory framework for target discovery. Given the tractability
of cell membrane receptors as drug targets, and the large number
of drugs that already target cell surface receptors, we aimed to
connect module expression to cell membrane receptors.
Starting from genome-wide gene expression proﬁling of the
epileptic mouse hippocampus, we ﬁrst identiﬁed co-expression
networks (modules) associated with the epileptic condition. The
cell-type speciﬁcity of these modules and their functional pro-
cesses was assessed using enrichment analyses, and the regulatory
inﬂuence of cell membrane receptors over the selected modules
was then inferred using gene regulatory information in a causal
reasoning framework (CRAFT).
Of the cell surface receptors predicted by CRAFT to inﬂuence
the expression one or more candidate epilepsy module, we chose
to validate Csf1R because of an absence of prior information
connecting Csf1R to epilepsy and the availability of a tool com-
pound (PLX3397) by which to test CRAFT’s predictions related
to Csf1R’s regulation of module 18 (and by extension module 18's
relationship to epilepsy). Analysis of module 18 expression in the
epileptic mouse brain revealed a PLX3397-dependent restoration
of module expression toward health. The predicted therapeutic
effect of PLX3397 on epilepsy was then conﬁrmed in three
independent models of epilepsy, including a mouse model of
pharmacoresistant epilepsy—a model in which traditional AEDs
at standard doses are ineffective. In addition to validating CRAFT
as a predictive framework for drug target discovery, these results
identify Csf1R inhibition as a potential novel therapeutic strategy
in epilepsy and provide further evidence to support the role of
innate immunity in the occurrence and maintenance of seizures
in acquired epilepsy14,43.
Csf1R is a membrane receptor expressed by myeloid lineage
cells including monocytes, macrophages, and microglia44. It has
been suggested that microglia are dependent on Csf1R signaling
for their survival such that brain microglia are reported to be
depleted from naïve mice following prolonged high dose treat-
ment with PLX3397 (5–6 times higher exposure than in our
study)33. In our study, we found no evidence for microglial
depletion by Csf1R in a series of ex vivo and in vitro experiments
and further we identiﬁed that the microglial marker Iba1 (enco-
ded by Aif1) is a predicted target of Csf1R and expected to be
down-regulated by Csf1R blockade. These results highlight the
dangers of interpreting reduced Iba1 expression as microglial cell
depletion. In our study, we present multiple layers of evidence
through genomic and microglial functional readouts to suggest
that PLX3397 has an effect on module 18 expression and
microglial phenotpye in the absence of microglial cell death.
The ability to map the landscape of a disease in terms of its
gene regulatory relationships offers considerable opportunities to
accelerate the drug discovery process. Although we took advan-
tage of experimentally validated interactions between TFs and
target genes and between membrane receptors and TFs, meta-
databases such as MetaBase® have limitations in terms of the
accuracy and completeness of this information, which places
restrictions on the scope and accuracy of our target predictions.
For example, the direction of effect of an interaction is often not
speciﬁed in a database, and the relationship between membrane
receptors and TFs is currently determined using linear pathways
where knowledge is still incomplete. However, as the complete-
ness of our knowledge of these regulatory relationships improves,
including more detailed knowledge of cell-type-speciﬁc interac-
tions between TFs and target genes, so the accuracy and scope of
CRAFT is also expected to improve. At present, the major chal-
lenge was to establish proof of concept that gene regulatory
knowledge combined with causal reasoning offers a valid fra-
mework for discovering mechanistically novel membrane recep-
tors as drug targets, and this is what the framework described
here makes possible. Although our causal reasoning framework
was implemented using regulatory interactions from Clarivate
Analytics MetaBase®, several other databases provide similar
sources of information that can be adapted to the CRAFT fra-
mework. For example, biological pathway databases such as the
Reactome pathway Knowledgebase45 and Pathway Commons46
provide well-characterized linear signaling pathways which can
be used to connect membrane receptors to TFs, whilst TF target
databases such as TRRUST47 provide information relating TFs to
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target genes. As well as having utility in prioritizing novel drug
targets for disease, CRAFT’s causal reasoning framework may
ultimately have broader biological value in terms of under-
standing and modulating maladaptive transcriptional responses
to environmental perturbations.
From a clinical perspective, our study identiﬁes Csf1R as a
novel drug target for acquired epilepsy, and highlights and further
supports the use of immunomodulatory therapies as a valid
therapeutic approach in acquired epilepsy48.
For this study, we chose to develop CRAFT using an estab-
lished mouse model of acquired epilepsy. This allowed for a
standardization of epilepsy cases and controls not possible with
human samples due to the substantial batch differences between
surgically resected hippocampi from living patients and control
post-mortem samples ascertained after death.
Unlike traditional gene expression analyses where power is
most often considered in terms of power to detect differentially
expressed genes (DEGs), for our study, power related to the
sample size required to detect differentially co-expressed mod-
ules. To investigate the effect of sample size on our ability to
detect modules which are differentially co-expressed between the
epileptic and control mouse hippocampus, we implemented a
post hoc permutation-based framework that preserves the real
data structure and employs random sub-sampling to determine
the minimum sample size necessary to identify differentially co-
expressed modules. Our simulations (Supplementary Figure 14)
revealed that some modules (e.g., module 18) can be detected
with as few as 20 epilepsy case and control samples, whilst for
others (e.g., module 12) differential co-expression between epi-
lepsy and control status can only be detected when the sample
size is much larger (n= 100).
In conclusion, CRAFT provides a gene regulatory and causal
reasoning framework to identify membrane receptors as novel
drug targets from gene expression data. As well revealing Csf1R
as a mechanistically novel target for acquired epilepsy, CRAFT
highlighted many other candidate regulators of epileptic networks
that may warrant further investigation as potential novel anti-
epilepsy drug targets. We therefore make our causal reasoning
framework in epilepsy and all its results available to the epilepsy
scientiﬁc community for unrestricted interrogation via a web
interface (http://ec2-54-191-145-199.us-west-2.compute.
amazonaws.com:3000/#/).
Methods
Mouse pilocarpine model of epilepsy. SE was induced in male Crl:NMRI(Han)-
FR mice (each mouse weighing 28–32 g at the beginning of the study) by a single
injection of pilocarpine as previously described22,49. Brieﬂy, animals were injected
intraperitoneally (i.p.) with 1 mg/kg of N-methylscopolamine bromide 30 min
prior to pilocarpine treatment (300 mg/kg; i.p.). Ten to forty-ﬁve minutes after
pilocarpine injection the animals displayed generalized clonic–tonic seizures that
progressed to continuous convulsive activity, that is, SE. The SE was allowed to
persist for 3 h and was then interrupted by i.p. injection of diazepam (10 mg/kg).
Mice surviving SE typically show spontaneous recurrent seizures (i.e., epilepsy)
within days to weeks and continue to have spontaneous seizures for several
weeks22,49. All mice underwent continuous monitoring for seizures for 14 con-
secutive days beginning 28 days following SE prior to sampling the hippocampus
and extraction of RNA. Seizure monitoring was performed with a proprietary
system (UCB Pharma) using simultaneous recording of locomotor activity with 3D
accelerometer and video. This system allows for automated detection of behavioral
seizures by analysis of the accelerometry signal, which is then reviewed manually
using the time-locked video recordings. All behavioral seizures were scored
according to the Racine’s50 method after careful review of corresponding video
clips by experienced technical personnel. Only secondary generalized seizures
Racine’s score 3–5 were quantiﬁed and used to calculate total seizure counts. Data
from 100 epileptic and age-matched and gender-matched control were included in
the study. All in vivo experiments were performed according to the National Rules
on Animal Experiments in Belgium and to the guidelines of the European Com-
munity Council Directive 2010/63/EU. Analyses were conducted under Imperial
College Research Ethics Committee approval ICREC_14_2_11. All efforts were
made to minimize animal suffering.
Post hoc sample size calculation. Unlike traditional gene expression analyses
where power is most often considered in terms of power to detect DEGs, for our
study, power relates to the samples size required to detect differentially co-expressed
modules. To investigate the effect of sample size on our ability to detect modules
which are differentially co-expressed between the epileptic and control mouse
hippocampus, we implemented a post hoc permutation-based framework that
preserves the real data structure and employs random sub-sampling to determine
the minimum sample size necessary to detect signiﬁcantly differential co-expressed
modules. This framework was implemented in three steps: (i) sample size was
randomly reduced in steps of 10% (i.e., 90, 80, 70, 60, 50, 40, 30, 20, and 10% of the
samples), (ii) the empirical signiﬁcance of differential co-expression was calculated
at each sample size, (iii) steps (i–ii) were performed 50 times to assess sampling
variation. We then selected three representative differential co-expression modules
associated with epilepsy in our study (M12, M18, and M21), which were each of
similar size in terms of the number of genes but which varied in terms of the mean
gene–gene correlation of each module. Using this permutation-based framework,
for each module, differential co-expression was assessed in terms of the empirical
signiﬁcance (P value) of the difference between the mean correlation of module
genes in epileptic versus control mice.
Our simulations revealed that as the sample size decreases there is an increase in
noise (measured as variation between each bootstrap permutation—the
interquartile range in the boxplots in Supplementary Figure 14) for both the
observed module correlations and the null distribution from the permutation. As
expected, for each module, there is an inverse relationship between effect size (i.e.,
the difference in mean correlation of module genes between conditions) and
sample size. Since mean gene–gene correlation varies between modules, the
differential co-expression of some modules (e.g., M18) can be detected with as few
as 20 mouse samples, while for others (M12 for example), the differential co-
expression between epilepsy and control status can only be detected when the
sample size is much larger—in the case of M12 only when sample size is n= 100.
These results show that some epilepsy modules would not have been reliably
detected as differentially co-expressed with a sample size less than n= 100.
Sample preparation for RNA-seq analysis. Total RNA was extracted from the
left hippocampus of each mouse (n= 200; 100 case and control mice). Sample
preparation for RNA-seq was performed according to the protocols recommended
by the manufacturers (TruSeq RNA Kit, Illumina). Sequencing was done using
Illumina HiSeq 2000 sequencer, with paired-end 75 bp nucleotide reads according
to the protocol recommended by the vendor. Raw reads were mapped to the
reference mouse genome (mm10) using TopHat version 2.0.851. Reads were
annotated using “union” gene model from HTSeq package version 0.6.
DE analysis. Genes were considered “expressed” and included in the analysis if
they had an expression value of Log2 FPKM >0 in at least 5% of the samples across
cases and controls. DE analysis was performed using the Bioconductor package
EdgeR, which implements generalized linear model based on negative binomial test
model for RNA-Seq in R52. P values were corrected for multiple testing using BH
FDR53. A cut-off of FDR ≤0.05 was applied to select DEGs.
Co-expression network analysis. Co-expression networks were constructed using
hierarchical clustering of normalized gene expression proﬁles from 100 epileptic
mice hippocampi. First, for all genes expressed in the hippocampus, we calculated
1-Spearman’s correlation coefﬁcients (called Spearman's distance) as a distance
metric between the expression of any two genes54–56. Second, the distances
between any gene pair were partitioned (clustered) using the Ward’s clustering
method57 and organized into a dendrogram. Brieﬂy, starting from the matrix of
Spearman distances, Ward’s method uses a recursive clustering procedure to form
partitions (clusters) of genes. At each step of the procedure, the Ward clustering
minimizes the loss of information (measured as the error of sum of squares in the
Spearman distances) associated with each grouping of genes. To identify discrete
clusters, we recursively cut the dendrogram to generate 299 clustering conﬁgura-
tions that included from K= 2 to K= 300 clusters. In order to identify the optimal
and stable number of clusters (Kx), we calculated the percentage of the variance
explained (R2) by each clustering conﬁguration (i.e., R2 for each considered K) as
follows:
Percentage of variance explained R2
  ¼ BSS
WSSþ BSS
where BSS (between sum of squares) is the between-groups variance in Spearman
distances and WSS (within sum of squares) is the within-groups variance in
Spearman distances. We used two criteria to choose the value Kx for which the
variance explained reaches a plateau, that is, there is no additional gain in infor-
mation (R2) when using the next clustering Kx+ 1 (Figure S1). The criteria used to
choose Kx were (1) the “Elbow” (or “knee”) method25 and (2) the pseudo F-
index58. Both criteria indicated an optimal and stable number of clusters, Kx= 29
(Figure S1).
Differential co-expression analysis. For each cluster the correlation between
gene expression proﬁles was computed in healthy and in epileptic animals
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separately and the difference in co-expression measure was based on Euclidian
distance between the two distributions (i.e., between healthy and epileptic mice).
The statistical signiﬁcance for the difference in co-expression was assessed
according to the null distribution generated by performing 10,000 permutations of
genes in the module27. This empirical P value of signiﬁcance was estimated for each
cluster and then corrected for the number of clusters tested for differential co-
expression using BH correction (BH-adjusted). A cluster was considered to be
signiﬁcantly differentially co-expressed if its BH-adjusted empirical P value was
<0.05.
Conservation in human TLE. Using the lists of genes from the co-expression
clusters in the mouse epileptic hippocampus, we ascertained “one2one” human
orthologs from the biomart Ensembl database. For epileptic cases, we used
genome-wide expression from whole human hippocampus samples from 122
epilepsy patients who had undergone selective amydalohippocampectomy for
mesial temporal epilepsy (mTLE) with hippocampus sclerosis (HS), downloaded
from GSE6380814. For non-epileptic controls (n= 63), we used genome-wide gene
expression data generated from 63 human hippocampus samples with no history of
neurological or psychiatric disease, downloaded from GSE4564231. The differential
co-expression test was performed as described above.
Association of co-expression modules with total number of seizures. First, the
frequency of behavioral seizures in each epileptic mouse was recorded by 14 days of
continuous motion sensing 3D accelerometry synchronized with continuous video
monitoring starting on day 28 post SE (as described above). Next, the relationship
between module expression and seizures was explored in two ways. First, we
explored the correlation between each module’s eigengene (i.e., its PC1) and seizure
frequency using Spearman’s correlation. Second, the relationship between the
expression of a module and seizures we explored by ﬁrst calculating the Spearman’s
correlation of expression of each individual gene in a module with seizure fre-
quency (termed QTT analysis29), and then tested the enrichment of each module
for genes individually correlated with seizure frequency (at FDR <0.05).
Cell-type enrichment analysis. Cell-type enrichment analysis was performed for
nine major cell types (cortical pyramidal neurons, CA1 pyramidal neurons,
interneurons, astrocytes, endothelial cells, mural cells, oligodendrocytes, ependymal
cells, and microglia) using marker gene signatures obtained from single-cell RNA-
seq of the mouse hippocampus26 (Fisher’s exact test). BH correction for multiple
testing was done and signiﬁcance threshold was at FDR ≤0.05.
Literature analysis to identify modules enriched in epilepsy-associated genes.
To extract epilepsy-associated genes from the scientiﬁc literature, gene–epilepsy co-
citation was searched in PubMed abstracts (3,811,179 abstracts, with at least one
gene–literature pair) using SCAIview webserver as available on 28 May 2014. The
weight of evidence relating a particular gene to epilepsy was then quantiﬁed by
determining if that gene’s co-citation with epilepsy (23,092 Abstracts with at least
one gene–epilepsy co-citation) was more frequent than expected by chance
(hypergeometric test). The list of epilepsy-associated genes was established by
applying a threshold of FDR ≤0.05. Then, by considering gene–epilepsy pairs
signiﬁcant at FDR <0.05, the modules were ranked according to their enrichment
of gene–epilepsy pairs (hypergeometric test).
In silico causal reasoning (CRAFT framework). To predict drug targets, we
aimed to connect disease-associated co-expression modules to regulatory TFs that
in turn can be modulated by membrane receptors. To implement this analysis, we
designed a causal reasoning framework that takes into account the direction of
effects between the three components of the system, that is, membrane receptor >
TF > target genes. The interactions between these three components and the
direction of these interactions were obtained from the Clarivate Analytics Meta-
Base® (version 6.15.62452, https://clarivate.com/products/metacore/), which is a
meta-database of manually curated literature-based contextual biological interac-
tions. Prior to the causal reasoning analysis, we removed all membrane receptors
and TFs that were not expressed in the mouse hippocampus, resulting in a list of
1624 TFs and 307 receptors, and we also considered only those target genes that
were expressed in the mouse hippocampus. Next, for each TF, we identiﬁed the set
of genes targeted by that TF and considered the activity of the TF on the target
genes in one or more of three possible categories: (a) genes activated by the TF
(act), (b) genes inhibited by the TF (inh), and (c) genes reported to be regulated by
the TF in MetaBase® but where the direction of the interaction was unknown (unk).
Next, the effect of each receptor on a TF was assessed using MetaBase® deﬁned
canonical linear pathways, with the direction of the effect of the membrane
receptor on the TF again considered as either activating (act), inhibitory (inh), or
unknown (unk). Note, hereon the term “regulator” can refer to either a TF or a
membrane receptor. The transcriptional effect of a regulator is deﬁned by the set of
target genes whose expression is predicted to be inﬂuenced by that regulator. For
regulators that are membrane receptors, the directionality of the receptors on
network expression was deﬁned by the causal reasoning rules set out in Table 1,
below.
Next, to assign directionality to the activity of a regulator in terms of disease
context, we considered the effect of the regulator on gene expression in the context
of whether the target genes in the co-expression module were over-expressed (“o”)
or under-expressed (“u”) in epilepsy. The set of genes in a module over-expressed
or under-expressed in epilepsy were termed “sub-modules” (of the parental
module). The signiﬁcance of effect of a regulator on a sub-module was then
assessed by testing the overlap between genes under the control of the regulator
(i.e., a membrane receptor or a TF) and the genes belonging to a sub-module
(hypergeometric test), taking all genes under the control of the regulator as the
universe. We report the effect of membrane receptors and TFs on sub-module gene
expression separately in Supplementary Data 10 and 11. FDR was calculated using
BH correction of enrichment P values, taking into account the total number of
enrichment tests performed. Regulators were considered to exert a signiﬁcant effect
on sub-module expression at FDR <0.05 and reported graphically in
Supplementary Figure 7. Because receptors may act via a number of different TFs,
and because TFs themselves may inﬂuence the expression of many genes,
sometimes in opposing directions, then for a regulator to be considered an
activator (act) of a sub-module, the regulator needed to exert a signiﬁcant (FDR
<0.05) positive effect on the expression of a sub-module but have no signiﬁcant
(i.e., FDR >0.05) negative effect on the sub-module’s expression. Similarly, for a
regulator to be considered an inhibitor (inh) the regulator should have a signiﬁcant
negative effect on sub-module’s expression (FDR <0.05) and no signiﬁcant positive
effect (FDR >0.05). Regulators with signiﬁcant (FDR <0.05) positive and negative
effects on sub-module expression were deemed to have an unspeciﬁed (uns) effect
on sub-module expression.
The impact of a regulator on sub-module expression was then quantiﬁed
according to the following two statistics:
1. The proportion of genes regulated by the “regulator” which are in the sub-
module= activity.
2. The proportion of genes in the sub-module that are under the control of the
regulator=weight.
Using these two values, regulators were ranked as follows:
(A) Absolute ranking: Regulators with a deﬁned impact, that is, “act” or “inh”,
were considered to have a higher priority over regulators with an unspeciﬁed
effect. The regulators were then sorted according to the sum of the ranks of
their activity and weight.
(B) Relative ranking: Because modules may be regulated by more than one
regulator, and because the target genes in a sub-module for each regulator
may overlap, where more than one regulator was identiﬁed, for each we re-
calculated the absolute rank based on the target genes not shared with the
previous regulator (based on the absolute rank list) in order to maximize
sub-module coverage and to identify potential synergistic combinations of
regulators. The ﬁrst regulator is the one with the highest absolute rank.
Pre-clinical evaluation of Csf1R blockade in mice. To evaluate the effect of Csf1R
blockade on gene network expression and epilepsy, we ﬁrst used a separate cohort
of chronic epileptic NMRI mice (pilocarpine model as above). All mice underwent
screening consisting of 7 continuous days (starting 6–7 weeks after pilocarpine-
induced SE) to conﬁrm the presence of spontaneous recurrent seizures (i.e., epi-
lepsy). During the eighth post SE week, n= 64 chronic epileptic mice (Racine’s
score 3–5) were video monitored (as described above) for a further 14 consecutive
days to establish their baseline seizure daily frequency, which was calculated by
dividing the total number of seizures by the exact duration of monitoring period.
Subsequently, the mice were randomly assigned into three separate groups (n=
21–22) to ensure comparable seizure frequency between the groups at baseline.
One group then received daily injections (oral gavage) with vehicle, while the two
other groups received the Csf1R inhibitor PLX3397 at 3 and 30 mg/kg per day for
14 days. All three groups were continuously monitored and their daily seizure
frequency was calculated and compared to baseline. To analyze the effect of
PLX3397 treatment on the daily seizure frequency, Wilcoxon's signed-rank test was
applied between the baseline and the treatment monitoring periods within each
treatment group. Mice were sacriﬁced for sampling of the brain on the day after the
last injection with either vehicle or PLX3397. Since in the pilocarpine model
symmetrical and bilateral pathology is observed in the brain, one hemisphere of the
brain was processed for immunohistochemistry (see below), while the
Table 1 Causal reasoning rules for membrane receptor
effects on target gene expression
Receptor Transcription factor Target genes
Act (+) Act (+) Activated
Act (+) Inh (−) Inhibited
Inh (−) Act (+) Activated
Inh (−) Inh (−) Activated
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hippocampus from the other hemisphere was used for RNA extraction and
microarray quantiﬁcation of mRNA expression.
Immunohistochemistry, image acquisition, and quantiﬁcation. Following brain
dissection, right brain hemispheres were immediately ﬁxed by immersion in 4%
paraformaldehyde overnight at 4 °C. Samples were rinsed in several changes of cold
1× phosphate-buffered saline (PBS), cryo-protected by overnight immersion in
15% sucrose solution at 4 °C, and then embedded in OCT (Tissue-Tek) and quickly
frozen over liquid nitrogen. Hemispheres were serially cut with a cryostat micro-
tome into 12 µm coronal sections that were mounted on slides and stored at –40 °C
until treatment. For immunohistochemistry, sections were rinsed twice in PBS, and
then incubated in PBS containing 0.3% Triton X-100 and 5% normal goat serum
(PBS-T) for 1 h at room temperature to block non-speciﬁc binding sites. Anti-Iba1
primary antibody (1:1000; rabbit; Synaptic Systems) was diluted in PBS-T and
applied on sections overnight at room temperature in a humidiﬁed chamber.
Labeling was visualized using Alexa Fluor secondary antibodies 488 (1:400; Invi-
trogen) and sections were counterstained with 4′,6-diamidino-2-phenylindole
(DAPI). Whole slide imaging was performed by ﬂuorescence microscopy using
NanoZoomer-XR with ×40 objective (Hamamatsu). Automatic quantiﬁcation of
cell density in speciﬁc brain regions was performed using the VisioPharm 5 soft-
ware (VisioPharm).
Total RNA extraction from hippocampi. Snap-frozen hippocampi were homo-
genized in RLT buffer (Qiagen, 74134) using Precellys® system in CK14 tubes
following the manufacturer’s instructions. Total RNA was obtained from mouse
hippocampi using RNeasy Plus Mini Kit (Qiagen, 74134) following the manu-
facturer’s instructions. RNA concentration was measured with a NanoDrop ND-
1000 Spectrophotometer. RNA quality was assessed using the Bio-Rad Experion
Automated Electrophoresis System (RQI ≥7).
Quantitative polymerase chain reaction. Complementary DNA (cDNA) was
synthesized from 1 µg total RNA using Applied Biosystems High-Capacity cDNA
Reverse Transcription Kit in a total volume of 100 µl following the manufacturer’s
protocol. qPCR reactions were performed using a CFX384 Real-Time System. Two
microliters of 2× diluted cDNA were analyzed in triplicate for genes of interest (see
Supplementary methods) expression using inventoried TaqMan® Gene Expression
Assays (ThermoFisher Scientiﬁc) and TaqMan® Universal PCR Master Mix
(ThermoFisher Scientiﬁc) in a ﬁnal volume of 10 µl according to the manu-
facturer’s recommendations. Cq values were obtained from the Bio-Rad CFX
Manager 3.1 software using regression determination mode. Normalized relative
expression levels were calculated using qbase+ software59 (Biogazelle NV, Zwij-
naarde, Belgium). Among eight genes, Brap and Bcl2l13 were identiﬁed with the
geNormplus60 module in qbase+ as the most suitable reference genes and were
used for normalization. One-tailed Welch’s t test was performed on Log 2-trans-
formed normalized expressions.
Microarray hybridization and analysis. The quality control (QC), RNA labeling,
hybridization, and data extraction were performed at GenomeScan/ServiceXS B.V.
(Leiden, The Netherlands). RNA concentration was measured using the Nanodrop
ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA).
The RNA quality and integrity was determined using Lab-on-Chip analysis on the
Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA, USA).
Biotinylated cRNA was prepared using the Illumina TotalPrep RNA Ampliﬁcation
Kit (Ambion Inc., Austin, TX, USA) according to the manufacturer’s speciﬁcations
with an input of 200 ng total RNA. Per sample, 750 ng of the obtained biotinylated
cRNA samples was hybridized onto the Illumina MouseRef-8 v2 (Illumina Inc., San
Diego, CA, USA). Hybridization and washing were performed according to the
Illumina Manual “Direct Hybridization Assay Guide.” Scanning was performed on
the Illumina iScan (Illumina Inc., San Diego, CA, USA). Image analysis and
extraction of raw expression data was performed with Illumina GenomeStudio
v2011.1 Gene Expression software with default settings (no background subtraction
and no normalization). QC and normalization of microarray data were performed
using “Lumi” package61 in R-Bioconductor62. Brieﬂy, samples that passed QC were
Log 2 transformed and normalized by quantiles between chips. DE was calculated
between the different groups using “Limma” package63 in R-Bioconductor.
Kainate-induced mTLE murine model. Kainate-induced mTLE model experi-
ments were performed at Synapcell SAS (38700 La Tronche, France). Animal
procedures were approved by the ethical committee of the High Technology
Animal Platform and performed in accordance with the European Community
Council Directive (2010/63/EU). Brieﬂy, C57/BL6 mice underwent surgery under
general anesthesia using isoﬂurane (3% in oxygen). Stereotaxic injection of 50 nl of
a kainic acid solution (1nmol) was performed in the right dorsal hippocampus (AP
=−2, ML=−1.5, DV=−2 mm with bregma as reference). After KA injection,
mice were implanted with a bipolar electrode in the ipsilateral dorsal hippocampus
and a reference electrode over the cerebellum. After surgery, animals were housed
in individual cages with access to food and water ad libitum under a 12/12 h light
and dark cycle. Eight mTLE mice underwent 2 h baseline EEG recording 4 weeks
after KA injection. Chronic treatment started after the baseline monitoring (D0),
where animals were injected daily p.o. (10 ml/kg) with 32.6 mg/kg of PLX3397 for
four consecutive days. PLX3397 was formulated in 1% (w/v) methylcellulose (400
cps), 0.1% (w/v) Tween-80, and 0.1% (w/v) silicone antifoam 1510 US in water. An
efﬁcacy EEG recording was performed for 2 h on the ﬁfth day (D5). EEG
recordings were analyzed for identiﬁcation/quantiﬁcation of HPDs. Individual data
were expressed as mean cumulated duration and mean number of HPDs per h over
the 2-h EEG recording period. The effect of the tested compound was compared
using one-way analysis of variance (ANOVA) for repeated measures followed by
paired comparison versus baseline period (D0).
Slope test. Slope test was performed to test the relationship between PLX3397
dose and restoration of network gene expression back to “normal.” The test was
performed using “smartr” version 3.4.3, R package, with null hypothesis that there
is no difference in the slopes obtained from two doses of PLX3397.
Organotypic hippocampal slice cultures. All animals used in this study were
performed according to the guidelines of the European Community Council
Directive 2010/63/EU. All experimental protocols using animals were reviewed and
approved by the ethical committee at UCB Biopharma. OHSCs were prepared
using polydimethylsiloxane mini-wells as described previously64. Brieﬂy, hippo-
campi were dissected from 6- to 9-day-old Sprague–Dawley rats and cut into 350-
µm-thick slices using a McIlwain tissue chopper. Slices were kept in ice-cold Gey’s
balanced salt solution containing 0.6% D-glucose and 300 µM kynurenic acid (all
from Sigma-Aldrich) for 30 min. After recovery, slices were washed three times
with the culture medium containing Neurobasal A, B27 supplement, 0.5 mM
Glutamax (all from ThermoFisher Scientiﬁc), and 30 µg/ml gentamicin (Sigma-
Aldrich). Only slices from the middle part of the hippocampus were selected and
placed in the center of the mini-wells, which allowed a good positioning over the
MEA assembly (200/30, 60 ITO from Multi Channel systems). For immunos-
taining experiments, slices were cultured on glass coverslips containing the mini-
wells in a 6-well culture plate. OHSCs were maintained in a humidiﬁed CO2
incubator at 35 °C and the medium was refreshed 2–3 times a week.
MEA recording and data analysis. An assessment of spontaneous epileptiform
activity was performed as described previously64. Field potential recordings were
performed once per slice at days in vitro (DIV) 8 (baseline before PLX3397
exposure) and then on DIV 15 and DIV 22, that is, after ﬁrst and second week of
exposure to 1 µM of PLX3397. Extracellular ﬁeld potential recording and stimu-
lation were performed using the MEA2100 system (2 × 60 channels, Multi Channel
Systems). OHSCs grown on MEAs at different DIVs were quickly moved to the
MEA recording chamber and spontaneous activity was recorded for 40 min using
the MC Rack software (Multi Channel Systems). The recording pads were pre-
heated at 35 °C and 95% O2/5% CO2 gas was continuously ﬂowing into the
chamber while recording. At the end of the recording, OHSCs showing no activity
or only interictal activity were further examined for viability and synaptic response.
Extracellular ﬁeld potentials were evoked in the CA1, CA3, and dentate gyrus (DG)
regions followed by biphasic current pulse stimulation (±30 μA) to Schaffer col-
laterals, stratum lucidum, and perforant path, respectively. Only slices showing
>500 μV of peak-to-peak ﬁeld excitatory postsynaptic potential amplitude in each
region were selected for data analysis. In the study, 9 of 60 slices showing only
interictal-like activity did not meet the QC criteria described above and therefore
were not included in the data analysis. Data were collected at 1 kHz sampling
frequency. Since epileptiform activity is highly synchronized in all subregions of the
hippocampus64, we chose one electrode in the DG granular cell layer to analyze
epileptic activity. Since cultured slices were required to adjust to the recording
chamber, we excluded signals from ﬁrst 10 min and only last 30 min of recorded
data were used for the data analysis. Automatic detection of ictal events was
performed using Labview (National Instruments). Interictal epileptiform dis-
charges were deﬁned as paroxysmal discharges that are clearly distinguished from
background activity, with an abrupt change in polarity occurring at low frequency
(<2 Hz). Ictal epileptiform discharges were deﬁned as paroxysmal discharges
lasting more than 10 s occurring at higher frequency (≥2 Hz). If the next ictal event
occurs within 10 s after the previous one, we considered the two as one ictal event.
LDH assay. Culture supernatants were collected on DIV 7 (baseline before
PLX3397 exposure) and then on DIV 14 and DIV 21, that is, after ﬁrst and second
week of exposure to 1 µM of PLX3397. Immediately after collection, the culture
supernatants were kept at −80 °C until the assay was performed. Experiment was
performed according to the manufacturer’s protocol. LDH was measured as a
maker of cell death65 using the LDH Assay Kit (BioVision). The culture super-
natants were diluted 2–3-folds with the assay buffer (BioVision) and colorimetric
signals were measured at 450 nm by a microplate reader FlexStation 3 (Molecular
Devices). LDH concentrations were calculated from the level of LDH activity that
converts nicotinamide adenine dinucleotide (NAD) to NAD reduced (NADH). The
concentration was expressed as mU/ml, where one unit of LDH generates 1 µM
NADH per minute. Statistical differences were assessed using the GraphPad Prism
v.7 software (GraphPad Software Inc., La Jolla, CA, USA) by two-way ANOVA
with Fisher's least signiﬁcant difference post hoc test. P < 0.05 was considered
signiﬁcant.
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Assessment of PLX3397 in acute seizure models. Animals: Male Crl:NMRI
(Han)-FR mice weighing 20–30 g were used in all experiments. The animals were
kept on a 12/12-h light/dark cycle with lights on at 0600 hours and were housed at
a temperature maintained at 20–21 °C and at humidity of about 40%. The mice
were housed in groups of 10 per cage (38 × 26 × 14 cm3). All animals had free
access to standard pellet food and water before random assignment to experimental
groups consisting of 10 mice each. All in vivo experiments were performed
according to the guidelines of the National Rules on Animal Experiments in Bel-
gium, ARRIVE, and the European Community Council Directive 2010/63/EU. All
efforts were made to minimize animal suffering.
Drug treatment: PLX3397 (3 and 30 mg/kg) was administered by oral gavage (p.
o.) in separate groups of animals (n= 10 per group). Mice received either a single
drug dose (acute treatment) or daily doses over 5 days (chronic treatment). Seizure
tests were performed 4 h after the single dose or the ﬁfth day of treatment, 4 h after
the last dose.
MES model: MES was produced by a stimulator (WITT IndustrieElektronik,
Berlin, Germany) using a current of 50 mA delivered with a pulse frequency of 50
Hz for 0.2 s through corneal electrodes66. A drop of 0.4% oxybuprocaine
hydrochloride (Unicaine, Thea, France) was placed on the eyes before electrical
stimulation. The mice were observed for 10 s following stimulation and the
incidence of tonic hindlimb extension was noted.
PTZ seizure threshold model: PTZ (intravenous) infusion was performed as
previously described66. Before infusion mice were brieﬂy restrained and a 30-gauge
needle attached to a 0.3-m-long polyethylene tubing (PE-10) was inserted into the
lateral tail vein. The needle was gently secured to the tail with plastic tape. The
tubing was connected to a syringe mounted on infusion pump (Harvard
Apparatus, Holliston, MA, USA). PTZ (5 mg/ml) (Sigma, Bornem, Belgium) was
infused at the rate of 0.25 ml/min in freely moving mice. The time from the start of
the infusion to the onset of myoclonic, clonic, and tonic convulsions was recorded.
The threshold doses of PTZ were calculated according to the following formula:
threshold dose (mg/kg)= (PTZ concentration (mg/ml) × infusion rate (ml/s) ×
infusion duration (s) × 1000)/weight of mouse (g)).
6 Hz model: The 6 Hz model was carried out according to a previously
described protocol66. Brieﬂy, corneal stimulation (44 mA, 0.2-ms-duration
monopolar rectangular pulses at 6 Hz for 3 s) was delivered by a constant-current
device (ECT Unit 57800; Ugo Basile, Comerio, Italy). A drop of 0.4%
oxybuprocaine hydrochloride (Unicaine, Thea, France) was placed on the eyes
before electrical stimulation. During the stimulation, mice were manually
restrained and released into the observation cage (38 × 26 × 14 cm3) immediately
after the current application. The seizures were often preceded by a brief period
(~2–3 s) of intense locomotor agitation (wild running and jumping). The animals
then exhibited a “stunned” posture associated with rearing, forelimb automatic
movements and clonus, twitching of the vibrissae, and strub tail. At the end of the
seizure, animals resumed their normal exploratory behavior. The animal was
considered as having a seizure if it did not resume its normal exploratory behavior
within 7 s from the stimulation. The duration and severity (Racine’s score) of
seizures was also noted.
Statistics: Seizure incidence data in the MES and 6 Hz models were compared
with Fisher’s exact test. Seizure duration and seizure severity data in the 6 Hz
model, as well as the threshold doses of PTZ for induction of myoclonic, clonic,
and tonic seizures were expressed as means ± SD and compared with one-way
ANOVA.
Microglia: gene expression and viability analyses. Primary microglia culture
and treatment: Primary microglia were collected from P7 brain of OF1 strain mice
(Charles River, L’Arbresle, France). Microglia was obtained after cell dissociation
and CD11B+ cell separation using Neural Tissue Dissociation Kit (P) and anti-
CD11B microbeads (Microglia) (MACS Technology), according to the manu-
facturer’s protocol (Miltenyi Biotec, Germany). Microglia were pelleted in
macrophage-serum-free medium (Gibco) supplemented with 1% P/S (Gibco). For
RNA-seq experiment, 1 ml/well of cell suspension at 6 × 105 cells/ml was plated in
12-well culture plates. For immunoﬂuorescence, 250 μL of cell suspension at 3 ×
105 cells/ml was plated in μ-Slide 8 Well Glass Bottom (Ibidi, Biovalley, France).
The medium was replaced 24 h later, and experiments started 24 h after replace-
ment of medium. Cells were treated with PLX 3397 1 µM (Selleckchem) or DMSO
(ﬁnal concentration 0.05%) for 30 min before adding PBS or mouse interleukin-1β
(50 ng/ml)+ interferon-γ (20 ng/ml) (R&D Systems). Twenty-four hours later,
media were removed and plates frozen at −80 °C for RNA-seq experiment. For
immunocytoﬂuorescence one positive control was added to other conditions using
4 h of incubation with staurosporine 1 µM (Abcam). Cells were ﬁxed at room
temperature with 4% formaldehyde for 20 min.
RNA extraction, quantiﬁcation, and quality: Total RNA from primary microglia
was extracted using NucleoSpin RNA XS according to the manufacturer’s
instructions (Macherey-Nagel, France). RNA concentration and quality were
assessed by spectrophotometry with the NanodropTM apparatus (ThermoFisher
Scientiﬁc, MA, USA) and Experion RNA StdSens Analysis Kit (Bio-Rad).
RNA-seq: mRNA was sequenced on Illumina HiSeq 4000 at an average read
depth of 40 million reads per sample.
Immunocytoﬂuorescence and quantiﬁcation: Immunoﬂuorescence staining on
ibidi chambers was performed at restroom temperature and started by 30 min of
incubation in a blocking buffer (PBS/3% bovine serum albumin (BSA)/0.3% Triton
X-100) followed by 2 h of incubation with biotinylated lycopersicon esculentum
(Tomato) lectin (1:500, Vector Laboratories) and rabbit anti-cleaved caspase-3
(Asp175) antibody (1:400, Cell Signaling) diluted in PBS/1% BSA/0.3%Triton X-
100. After rinsing with PBS, cells were incubated 1 h with streptavidin Cy3 (1:1000,
ThermoFisher Scientiﬁc) and donkey anti-rabbit Alexa 488 (1:1000, ThermoFisher
Scientiﬁc) followed by a counterstaining with DAPI.
Fives pictures per well were made using Nikon Eclipse Ti-E microscope (×10)
and ﬁelds were automatically deﬁned by the software not by the experimenter. An
experimenter blind to treatment group performed all analyses. All cells were
Tomato lectin positive (TL+). The number DAPI+ nucleus was counted as well as
the cleaved caspase-3+ cells using the Fiji Software. The number of DAPI+
nucleus and cleaved caspase-3+ cells were expressed per mm2.
Microglia: phenotype and viability analyses. Primary microglia cell culture:
Forebrains were isolated from post-natal day 7–8 (P7–8) mice (C57BL/6J) and
meninges were carefully removed. Brains were dissociated using the Papain Dis-
sociation System (Worthington) according to the manufacturer’s instructions.
Homogenates were ﬁltered through a 40 µm cell strainer (Falcon) and re-
suspended in complete medium: DMEM GlutaMAX (ThermoFisher Scientiﬁc)
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (P/S)
(ThermoFisher Scientiﬁc). Single-cell suspensions were then transferred into T75
ﬂasks and incubated at 37 °C in 5% CO2 for 1 week. Microglia were isolated from
mixed glial cell cultures by shaking ﬂasks for 1 h at 200 rpm at 37 °C, re-suspended
in complete medium with 20 ng/ml M-CSF (R&D Systems) and grown for 7 days
in 2-well culture insert 24-well (Ibidi) or 96-well (Greiner) plates.
Scratch wound migration assay: Primary microglia were seeded at a density of
30,000 cells per insert in 2-well culture insert 24-well plates (Ibidi). Cells were
incubated at 37 °C in 5% CO2 until reaching approximately 80% conﬂuence.
Culture inserts were then carefully removed followed by washing of the cell
monolayer with fresh complete medium and imaging of the scratch area using an
EVOS digital inverted light microscope. Primary microglia were treated with 1 µM
of PLX3397 for 24 h and the scratch area re-imaged. Microglia cell migration into
the scratch area was quantiﬁed using ImageJ.
LDH assay: Cell death activity in brain slice culture was measured in slice-
bathing ﬂuids collected 4 h after exposure to zymosan beads. The LDH Activity
Colorimetric Assay Kit (BioVision) was used following the manufacturer’s
instructions.
Live/dead assay: Primary mouse microglia isolated and cultured as described
above were exposed to vehicle (medium+ 0.01% DMSO) or 1 µM PLX3397 for 24
h at 37 °C at 4% CO2. Cell viability was measured using a LIVE/DEAD Viability/
Cytotoxicity Kit as per the manufacturer’s instructions (ThermoFisher Scientiﬁc).
Labeled cells were ﬁxed and imaged using a Zeiss AxioObserver Z1 ﬂuorescent
microscope (Zeiss).
Ex vivo phagocytosis assay using acute brain slices: After exposure to isoﬂurane,
PLX3397-treated pilocarpine mice were decapitated and brains rapidly dissected.
Sagittal sections were generated at 300 µm thickness using a Leica VT 1200S
vibratome (Leica) in ice-cold carbogen (95% CO2, 5% O2)-bubbled artiﬁcial
cerebrospinal ﬂuid solution (aCSF) consisting of 126 mM choline chloride, 3 mM
KCl, 2.4 mM CaCl2, 1.3 mM MgCl2, 26 mM NaHCO3, 1.24 mM NaH2PO4, and 10
mM glucose. Slices were immediately placed for 1 h at 35 °C in incubation
chambers (Prechamber BSC-PC, Harvard Apparatus) ﬁlled with carbogen-bubbled
aCSF (with choline chloride replaced by a stoichiometric amount of NaCl). Slices
were then incubated for 1 h at 37 °C followed by incubation with pH Rodo-
conjugated zymosan bioparticles and prepared as per the manufacturer’s
instructions (ThermoFisher Scientiﬁc) at 37 °C for 1 h. After washing slices with
PBS, they were ﬁxed in 4% paraformaldehyde for 1 h at room temperature before
immunostaining. Fixed slices were incubated for 3 h with blocking solution
(normal goat serum 5%, 0.05% Triton X in PBS) and incubated for 48 h with
primary antibody: anti-Iba1 (Synaptic Systems, 234004). Slices were washed 3× for
15 min in PBS and incubated with secondary antibody (anti-guinea pig IgG, Alexa
488; ThermoFisher Scientiﬁc) for 3 h at room temperature. After washing in 1×
PBS, slices were counterstained with DAPI and mounted. Images were acquired
using the Zeiss LSM880 confocal microscope (Zeiss) and the number of particles
engulfed by Iba1+microglia and the number of phagocytic microglia counted.
Microglia morphology analysis: Multiple Z-stack images (×63 objective, Zeiss
LSM880) were captured from random areas of vehicle-treated and PLX3397-
treated pilocarpine brain sections and processed using the Zeiss ZEN 2.3 software
(Zeiss). These images were then used for microglia morphology analysis using the
ImageJ plugin NeurphologyJ Interactive to measure microglial soma number/area
and process number/area.
Statistical analysis: Results are presented as means ± standard error of the mean
(SEM). Statistics were calculated using the GraphPad Prism 7 using two-tailed
Student’s t test.
PLX3397 PKs in mouse plasma and brain. PLX3397 at 30 mg/kg (p.o.) was
administered in naïve male NMRI (Naval Medical Research Institute) mice (n=
2–4). Plasma samples were taken at 0.25, 0.5, 1, 2, and 6 h after dosing, while
terminal plasma and brain samples were collected 24 h after dosing. In addition,
pilocarpine NMRI mice (n= 8) were dosed at 3 and 30 mg/kg (p.o.), once a day for
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1 week, and terminal plasma and brain samples were taken 24 h after the last
administration and analyzed by liquid chromatography with tandem mass spec-
trometry bioanalytical method. The relationships between peak area ratio (analyte/
IS) and plasma concentration was linear over the range of 20–50,000 ng/ml for
PLX3397. The relationships between peak area ratio (analyte/IS) and brain con-
centration was linear over the range of 100–250,000 ng/g for PLX3397. Data are
submitted to a 1/x2 weighing factor and UCB30542 is used as an internal standard
for PLX3397. Raw data were smoothed (no. of smooths: 3), peaks were auto-
matically integrated and integrations were checked individually.
Data availability
The RNA-seq data generated in this study (a) to build gene co-expression modules and
(b) to assess effect of PLX3397 on the microglial transcriptome have been submitted to
the European Nucleotide Archive (ENA)) under accession numbers PRJEB18790 and
PRJEB27765 (https://www.ebi.ac.uk/ena/data/view/PRJEB18790 and https://www.ebi.ac.
uk/ena/data/view/PRJEB27765), respectively. The gene expression data generated to
assess the transcriptional effects of PLX3397 in the pilocarpine model of epilepsy has
been submitted to NCBI Gene Expression Omnibus (GEO) under accession number
GSE77578 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE77578).
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